

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 21865-0002001	Application No. 10/718,986
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Yu et al.	
		Filing Date November 21, 2003	Group Art Unit 1652

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1						
	2						
	3						
	4						
	5						
	6						
	7						
	8						
	9						
	10						
	11						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	12	WO93/03708	3/4/1993	WIPO			Yes	
	13							
	14							
	15							
	16							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	17	Ah-Tse et al., "Virus-Receptor Interactions of Human Parainfluenza Viruses Types 1,2 and 3", <i>Microbial Pathogenesis</i> , 27: 329-336, 1999
	18	Anderson et al., "Mucins and Mucoids in Relation to Influenza Virus Action. VI. General Discussion", <i>Walter and Eliza Hall Institute of Medical Research, Melbourne</i> , 403-411, 1948
	19	Anderson, "Mucins and Mucoids in Relation to Influenza Virus Action, 1. Inactivation by RDE and by Viruses of the Influenza Group, of the Serum Inhibitor of Haemagglutination", <i>Walter and Eliza Hall Institute of Medical Research, Melbourne</i> , 347-354, 1948
	20	Byron et al., "Drug Delivery Via The Respiratory Tract", <i>Journal of Aerosol Medicine</i> , 7(1):49-75, 1994

Examiner Signature /Tekchand Saidha/ (05/11/2010)	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.S./

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 21865-0002001	Application No. 10/718,986
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Yu et al.	
		Filing Date November 21, 2003	Group Art Unit 1652

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	21	Granoff & Webster, R. G., ed. "Influenza Viruses (Orthomyxoviridae)", <i>Encyclopedia of Virology: 2nd Edition</i> , Volume 2, 824-841, 1999
	22	Johnson et al., "Heparan Sulfate is Essential to Amphiregulin-induced Mitogenic Signaling by the Epidermal Growth Factor Receptor", <i>Journal of Biological Chemistry</i> , 269(43):27149-27154, 1994
	23	Jones et al., "Caprine Mucopolysaccharidosis-IIID: Clinical, Biochemical, Morphological and Immunohistochemical Characteristics", <i>Journal of Neuropathology and Experimental Neurology</i> , 57(2): 148-157, 1998
	24	Moscona et al., "Analysis of Human Parainfluenza Virus 3 Receptor Binding Variants: Evidence for the Use of a Specific Sialic Acid-Containing Receptor", <i>Microbial Pathogenesis</i> , 20:179-184, 1996
	25	Moscona, "Entry of Parainfluenza Virus into Cells as a Target for Interrupting Childhood Respiratory Disease", <i>The Journal of Clinical Investigation</i> , 115(7):1688-1698, 2005
	26	Moscona et al., "Fusion Properties of Cells Persistently Infected with Human Parainfluenza Virus Type 3: Participation of Hemagglutinin-Neuraminidase in Membrane Fusion", <i>Journal of Virology</i> , 65(6):2773-2777, 1991
	27	Moscona et al., "Fusion Properties of Cells Infected with Human Parainfluenza Virus Type 3: Receptor Requirements for Viral Spread and Virus-Mediated Membrane Fusion", <i>Journal of Virology</i> , 66(11):6280-6287, 1992
	28	Meuller et al., "Structure, binding and antagonists in the IL-4/IL-13 receptor system" <i>Biochim. Biophys. Acta.</i> , 1592:237-250, 2002
	29	Palermo et al., "Human Parainfluenza Virus Infection of the Airway Epithelium: Viral Hemagglutinin-Neuraminidase Regulates Fusion Protein Activation and Modulates Infectivity", <i>Journal of Virology</i> , 83(13):6900-6908, 2009
	30	Wills-Karp et al., "Interleukin-13 in asthma." <i>Curr. Opin. Pulm. Med.</i> , 9:21-27, 2003
	31	Zhang, "Concerns of using Sialidase Fusion Protein as an experimental drug to Combat Seasonal and Pandemic Influenza", <i>Journal of Antimicrobial Chemotherapy Advance Access</i> , 66:426-428, 2008
	32	Zhang et al, "Infection of Ciliated Cells by Human Parainfluenza Virus Type 3 in an In Vitro Model of Human Airway Epithelium", <i>Journal of Virology</i> , 79(2):1113-1124, 2005

Examiner Signature /Tekchand Saidha/ (05/11/2010)	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	